Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2003

View Archived Issues

Phase II findings for onercept in psoriasis and psoriatic arthritis

Peregrine presents antibodies targeting phosphatidylserine

Applied Molecular Evolution to optimize Lilly protein therapeutic candidates

Gilead and Bukwang clevudine licensing agreement terminated

Curis collaboration focusing on Hedgehog signaling pathway

Lorus selects lead antisense compound to target thioredoxin

Inflazyme completes acquisition of GlycoDesign

Y-700 found to inhibit uric acid formation in healthy adult volunteers

SCV-07 stimulates Th1 immune response in TB animal model

Analgesic effects reported for gabapentin in chronic radiculopathy

SMP-114 has good safety profile in healthy volunteers

Durable clinical response found for alefacept plus methotrexate in severe rheumatoid arthritis

Clinical benefits of a human monoclonal antibody against IL-15 in active rheumatoid arthritis

Three series of CCR3 antagonists with utility in asthma therapy claimed by Roche

New GABA-C receptor antagonists and their use as cognition-enhancing agents

Antitumor epothilones identified by Kosan scientists

Pharmacia (Pfizer) team identifies novel pyrazine-based CRF1 antagonists

Apoptosis inducers prepared and tested at the Burnham Institute

Scientists at Fujisawa and Daiso present novel apo B secretion inhibitors

New factor Xa inhibitors and their use covered by Warner-Lambert patent

Idec and Biogen to merge

Enbrel recommended by FDA panel to treat ankylosing spondylitis

Savient chosen as new corporate name for Bio-Technology General

Pilot study of Probuphine initiated for treatment of opiate addiction

MLN-2201 enters phase I testing

CPMP hands down positive opinion for survival claim for MabCampath

European Commission grants marketing authorization for Aldurazyme in Europe

FDA clears IND for dextofisopam for IBS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...